Recommended

GSK appoints new CEO
New webinar | Addressing the time-to-result challenge posed by short shelf-life radiopharmaceuticals, register today
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

Moderna to obtain first acquisition for $85 million

0
SHARES

Moderna has agreed on its first acquisition for $85 million, enabling it access to cell-free DNA synthesis and amplification technologies.

Moderna to obtain first acquisition for $85 million - cell-free DNA synthesis

Moderna, Inc. is set to acquire OriCiro Genomics K.K. for $85 million, who will provide expertise on cell-free DNA synthesis and amplification technologies.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

“With this acquisition, we obtain best-in-class tools for cell-free DNA synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing,” commented Stéphane Bancel, Chief Executive Officer of Moderna.

Moderna’s mRNA therapeutics strategy

2022 was a pivotal year for Moderna, the company‘s CEO noted in a recent statement. Moderna’s two Omicron-targeting bivalent COVID-19 vaccines have been approved in more than 70 countries. Its platform technology also delivered the world’s first-ever mRNA cancer treatment that showed efficacy in a randomised Phase II study, demonstrating the potential of personalised medicine.

At the end 2022, Moderna, Inc. finalised a strategic partnership to create a state-of-the-art mRNA vaccine research, development, and manufacturing facility in the UK. The site, called the Moderna Innovation and Technology Centre (MITC) is designed to provide access to a UK-made supply of COVID-19 vaccines. The facility also offers potential for the development of vaccines for other respiratory illnesses, such as flu and respiratory syncytial virus (RSV).

The future mRNA therapeutic market

A 2022 market report forecasted that mRNA non-vaccine therapeutics are set to generate $2 billion in sales by 2028. The research found that since the COVID-19 pandemic, there has been a spike in interest in mRNA therapeutics, due to the success of mRNA vaccines treating the virus.

mRNA therapeutics: a limitless revolution in medicine

Share via
Share via